DEC 02, 2016 2:35 PM PST

Legal Ecstasy May Become the New PTSD Drug

WRITTEN BY: Xuan Pham
Post-traumatic stress disorder (PTSD) affects millions of people, but the disorder is notoriously difficult to treat. Even with our best treatment efforts, researchers say a significant portion of patients are still left behind.
 
But recently, the psychedelic MDMA, otherwise known colloquially as “ecstasy,” is gaining traction as an unconventional but effective treatment for PTSD. Furthermore, the FDA also saw the potential in this drug, and has approved it in a large-scale clinical trial for PTSD. The move could pave the way for legally prescribed “ecstasy” as a psychotherapy agent in the future.
 
Known on the street as “E,” “Molly,” and “millennial aspirin,” MDMA (3,4-Methylenedioxymethamphetamine) is a popular recreational psychedelic drug. The compound acts on the amygdala to induce feelings of euphoria, empathy, and otherwise heightened emotions.
 
Heavy abuse of the drug – leading to addiction, memory issues, paranoia, and other adverse symptoms – led the FDA to classify it as a Schedule 1 substance and its eventual ban. However, many researchers saw potential in MDMA as a psychotherapy drug, precisely because of how it affects the brain.
 

In a few early stage clinical trial of MDMA, patients reported working through their trauma in ways that could not be replicated with conventional treatments. One study found a 56 percent decrease in the severity of their PTSD symptoms with the use of MDMA. This shift led more than two-thirds of the patients to free themselves from the diagnosis of PTSD – a remarkable outcome considering the ineffectiveness rate of current therapies. Furthermore, the results seem to have a lasting effect, even after the drug was discontinued.
 
“The body of evidence that shows MDMA works is so strong and so encouraging,” said Rick Doblin, the founder and executive director of Multidisciplinary Association for Psychedelic Studies (MAPS), which is sponsoring the current Phase III clinical trial, involving over 200 participants.
 

In addition to obtaining the unprecedented OK from the FDA to use MDMA in the clinical trial, the team also applied for the “breakthrough therapy” status. This designation is typically reserved for drugs that can “treat a serious or life threatening disease or condition.” If granted and trial results prove promising, MDMA can be on the fast track for approval as a PTSD psychotherapy drug by as early as 2021.
 
Of note, researchers underscore that the trial is to expand the psychedelic’s medicinal uses, not its recreational potential. So to people who doubt the safety of legal ecstasy, Doblin says: “This is never going to be a take-home drug. It’ll only be prescribed by doctors with special training, for people with specific conditions.”

Additional sources: NY Times, Popular Science
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 14, 2020
Clinical & Molecular DX
Urchin-shaped DNA Biosensor Detects Disease Earlier
APR 14, 2020
Urchin-shaped DNA Biosensor Detects Disease Earlier
For researchers at the Missouri University of Science and Technology developing a new class of nanodiagnostics, good thi ...
APR 29, 2020
Clinical & Molecular DX
Move and Detect : Diagnosis of Neonatal Sepsis Using Fluorescent Micromotors
APR 29, 2020
Move and Detect : Diagnosis of Neonatal Sepsis Using Fluorescent Micromotors
According to the World Health Organization (WHO), sepsis occurs when the body’s response to an infection injures i ...
MAY 05, 2020
Clinical & Molecular DX
A High Resolution Glimpse Inside the Brain
MAY 05, 2020
A High Resolution Glimpse Inside the Brain
Imagine a future where we could “see” inside the human brain at stunning high resolution, detecting the earl ...
JUN 09, 2020
Clinical & Molecular DX
The Key to Unlocking Next Generation Wearable Biosensors Is Under the Sea
JUN 09, 2020
The Key to Unlocking Next Generation Wearable Biosensors Is Under the Sea
Wearable biosensors are the latest trend in health and diagnostic technologies — keeping track of everything from ...
AUG 07, 2020
Cancer
Immune-Related Genes as Prognostic Biomarkers
AUG 07, 2020
Immune-Related Genes as Prognostic Biomarkers
Cancer is one of the most persistent and hardy diseases. Cancers often develop the ability to suppress the immune system ...
AUG 11, 2020
Clinical & Molecular DX
Supervillain Alert! New Tech IDs Drug-Resistant Superbugs.
AUG 11, 2020
Supervillain Alert! New Tech IDs Drug-Resistant Superbugs.
The human body is made up of around 10 trillion cells. Fascinatingly, we have 10 times more bacterial cells on our bodie ...
Loading Comments...